Abstract 214P
Background
Small cell lung cancer (SCLC) is currently treated with a combination of chemotherapy and immunotherapy. Unfortunately, not all patients benefit from this regimen and few alternative therapies are available. Based on recent transcriptomic data defining an “inflamed” subtype of SCLC patients who benefit from immunotherapy, we hypothesised that innate immune activation and natural killer (NK) cells may provide an opportunity to evaluate immune-responsive patients.
Methods
SCLC patients receiving two cycles of chemo-immunotherapy were divided into best responders (BR) and non-responders (NR). NK cells from SCLC patients (n=10) were isolated from peripheral blood-collected PBMCs and subjected to RNA-seq and gene set enrichment analysis (GSEA). Isolated NK cells were in vitro treated with DNA-dependent protein Kinase (DNA-PK) inhibitor. RT-PCR, Seahorse assay and flow cytometry were performed to investigate immune checkpoint expression.
Results
GSEA analysis of RNAseq data on NK cells from BR patients of SCLC cohorts showed high levels of IFN-related pathways (IFN_GAMMA_RESPONSE NES=2.77; p<0.0001, IFN_ALPHA_RESPONSE NES=2.49; p<0.0001) and Influenza infection (NES=3.57; p<0.0001) enrichment in BR patients derived NK cells in comparison to NR patients. In addition, NK cells from BR patients showed enrichment in oxidative phosphorylation genes (NES=2.14; p<0.0001) as well as DNA repair pathway (NES=2.07; p<0.0001). ISMARA analysis revealed that BR patients-derived NK cells showed high Interferon regulatory factor 3 (IRF3)-binding motif (Pearson corr. coeff. = 0.76; p<0.0001) compared to the NR cohort. In vitro treatment of NK cells with DNA-PKi significantly increased multiple innate immunity cytosolic DNA/RNA sensors, namely cGAS-STING (p < 0.0001), MAVS (p < 0.0001) and IFI16 (p < 0.0001). Finally, metabolic analysis showed an increase in ATP production Rate and phenotypic characterization by flow cytometry showed an increase in ICOS (CD278) expression in DNA-PKi- treated NK cells.
Conclusions
Comprehensive transcriptomic analysis of SCLC-isolated NK cells revealed significant positive modulation of innate immune pathways, suggesting a potential role for DNA-PKi in metabolic and phenotypic remodelling.
Legal entity responsible for the study
The authors.
Funding
Associazione Italiana per la Ricerca sul Cancro (AIRC).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
Resources:
Abstract
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
Resources:
Abstract
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
Resources:
Abstract
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
Resources:
Abstract
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract